Prime Medicine: A Startup Biotech Delivering on the Promise of Prime Editing

On July 13, 2021, Prime Medicine, a pre-IPO biotech company delivering on the promise of Prime Editing to provide lifelong cures to patients, announced its launch with $315 million in financing. Prime Editing, a versatile gene editing technology that can truly “search and replace” to restore normal gene function and address the fundamental causes of disease is co-founded by David R. Liu and Andrew Anzalone at the Broad Institute of MIT and Harvard, who worked together and published this groundbreaking new technology in a landmark Nature paper in 2019. Base editing and prime editing are next-generation CRISPR technologies that let scientists modify the genome more efficiently and precisely than ever before, offering unprecedented opportunities to correct up to 89% of known genetic variants associated with human diseases.

According to Prime Medicine, Prime Editing is a next-generation gene editing technology that acts like a DNA word processor, with the power to “search and replace” genetic sequences at their exact location in the genome, all without making double-strand breaks in DNA.

Join Robinhood with my link and we'll both get a free stock 🤝
https://join.robinhood.com/zhijiec

My Favorite Books on Biotech and Investing
The Code Breaker: Jennifer Doudna, Gene Editing, and the Future of the Human Race
https://amzn.to/3rgGAve

#PrimeMedicine
#PrimeEditing
#CRISPR
#GeneEditing
#GenomeEditing
#DavidLiu
#PrimeEditor
#BaseEditing
#GeneticDisease
#Cas9
#BiotechInvestor

0:00 Prime Medicine Launched with $315 Million
1:13 The Science of Prime Editing
2:28 Prime Editor: How Does it Work?
3:20 David Liu on the Invention of Prime Editing
12:08 Features of Prime Editing
14:00 Subscribe for Future Updates

***Disclaimer
I (Biotech Investor) hold a Ph.D. degree in life science and conducted 5 years of postdoctoral training in molecular biophysics at UC Berkeley. I am currently a full-time employee of a clinical-stage biopharmaceutical company, conducting early-stage drug discovery research. I have no professional affiliation with any of the companies or stocks discussed on this channel. This video is strictly for educational and entertainment purposes, and none of the contents in the video are for medical or financial/investment advice. I have no obligation to update, change or correct any information described in this video as news and stock prices change. The thoughts described in this channel are my own and do not reflect the company that I work for. This is not a solicitation to invest in any company I discussed in this channel, and I am not a financial or medical advisor. Investment involves risks and past performance should not be used as a gauge for future success. Seek a financial advisor to determine the appropriate investment strategies for your given circumstances. Investors should obtain their own independent financial advice and understand the risks associated with investment products/ services before making investment decisions.